Compounds > gefitinib
Page last updated: 2024-09-03

gefitinib and enzastaurin

gefitinib has been researched along with enzastaurin in 5 studies

Compound Research Comparison

Studies
(gefitinib)		Trials
(gefitinib)		Recent Studies (post-2010)
(gefitinib)		Studies
(enzastaurin)		Trials
(enzastaurin)		Recent Studies (post-2010) (enzastaurin)
5,2315662,9191885299

Protein Interaction Comparison

ProteinTaxonomygefitinib (IC50)enzastaurin (IC50)
Protein kinase C gamma typeHomo sapiens (human)0.7915
Protein kinase C alpha typeRattus norvegicus (Norway rat)0.7
Protein kinase C beta typeHomo sapiens (human)0.1797
Protein kinase C delta typeRattus norvegicus (Norway rat)0.7
Protein kinase C epsilon typeRattus norvegicus (Norway rat)0.7
Protein kinase C zeta typeRattus norvegicus (Norway rat)0.7
Protein kinase C alpha typeHomo sapiens (human)0.4695
Protein kinase C eta typeHomo sapiens (human)0.4
Protein kinase C gamma typeRattus norvegicus (Norway rat)0.7
Protein kinase C beta typeRattus norvegicus (Norway rat)0.7
Protein kinase C epsilon typeHomo sapiens (human)0.38
Protein kinase C zeta typeHomo sapiens (human)8
Protein kinase C delta typeHomo sapiens (human)1
Calcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)10
Calcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)10
Calcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)10
Protein kinase C eta typeRattus norvegicus (Norway rat)0.7
Calcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)10
Protein kinase C theta typeRattus norvegicus (Norway rat)0.7

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Stummer, W1
Bianco, R; Caputo, R; Ciardiello, F; Damiano, V; Daniele, G; Gelardi, T; Lahn, M; Pepe, S; Tortora, G1

Other Studies

5 other study(ies) available for gefitinib and enzastaurin

ArticleYear
Comprehensive analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2011, Oct-30, Volume: 29, Issue:11

    Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity

2011
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017
Perspectives in central nervous system malignancies.
    IDrugs : the investigational drugs journal, 2006, Volume: 9, Issue:6

    Topics: Antineoplastic Agents; Central Nervous System Neoplasms; Combined Modality Therapy; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Glioma; Humans; Indoles; Protein Kinase C; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Randomized Controlled Trials as Topic; Sirolimus; TOR Serine-Threonine Kinases

2006
Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs.
    British journal of cancer, 2008, Aug-05, Volume: 99, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Culture Media, Conditioned; Drug Screening Assays, Antitumor; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Gefitinib; Humans; Indoles; Mice; Mice, Nude; Phosphatidylinositol 3-Kinases; Quinazolines; Vascular Endothelial Growth Factor A

2008